CJC-1295 DAC
CJC-1295 with Drug Affinity Complex (DAC)
A long-acting GHRH analog with a Drug Affinity Complex (DAC) that binds to albumin in the bloodstream, extending its half-life from minutes to approximately 8 days. Produces sustained elevation of GH and IGF-1 levels.
Mechanism of Action
CJC-1295 DAC binds GHRH receptors on pituitary somatotrophs, stimulating GH release. The DAC technology (maleimidoproprionic acid) covalently binds to albumin via a Michael addition reaction, dramatically extending the half-life. This produces a sustained 'GH bleed' rather than pulsatile release.
Health Claims & Evidence
Sustained elevation of GH and IGF-1 levels
Promotes lean muscle mass accretion
Reduces body fat, particularly visceral fat
Short-Term Effects
Improved sleep quality, increased energy, and enhanced recovery within 2–4 weeks.
Long-Term Effects
Progressive lean mass gain and fat loss over 8–16 weeks.
Side Effects
Water retention, joint pain, carpal tunnel symptoms, insulin resistance at high doses, potential IGF-1-related risks.
Contraindications
Active malignancy, diabetic retinopathy, carpal tunnel syndrome. Use with caution in insulin resistance.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
CJC-1295 and growth hormone release
Jetté et al. · Journal of Clinical Endocrinology & Metabolism · 2005
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on CJC-1295 DAC and related peptides, and prepare an educational research summary.
Explore Research